[Skip to Content]

NICE rapid review of the use of fluocinolone acetonide for chronic DMO

Oct 01

College Statment Since the release of TA 2711 in January 2013, NICE has undertaken a rapid review of the use of fluocinolone acetonide for chronic diabetic macular oedema2 and has recently released the FAD document for this single technology appraisal3. In the FAD document, the following guidance has been issued: Fluocinolone acetonide intravitreal implant is

  • 1 October 2013

NICE guidance on Ocriplasmin

Sep 17

College Statement Ocriplasmin is a recombinant protease enzyme that is effective in lysing fibronectin and laminin bonds at the vitreoretinal interface thus relieving vitreoretinal traction following intravitreal injection. Pivotal phase III trials have shown its effectiveness in treating vitreomacular traction leading to European Union approval in March 2013. The Royal College of Ophthalmologists welcomes the

  • 17 September 2013

Updated Public Health Outcomes Framework eye health indicator figures

Aug 24

The Public Health Outcomes Framework (PHOF) eye health indicator figures have been updated http://www.phoutcomes.info/ New baseline data have been published for Preventable sight loss indicators(4.12 i “ Preventable sight loss – age related macular degeneration (AMD)”, 4.12 ii “ Preventable sight loss – glaucoma”, 4.12 iii “Preventable sight loss – diabetic eye disease”, 4.12 iv “Preventable

  • 24 August 2013

Our ophthalmology service is ‘failing’ – please help

Aug 15

An important part of the Professional Standards Committee’s work is to provide advice to providers or commissioners of ophthalmology services where something has gone wrong with a clinical service, where concerns have been raised about the clinical care provided, or where an eye department is in dispute with its host trust. Although the College has

  • 15 August 2013

Positive draft final guidance from NICE for Eylea® for the treatment on wet AMD

May 31

College Statement The Royal College of Ophthalmologists welcomes the NICE draft final guidance which announces that Eylea® (aflibercept) should be recommended for the treatment of patients with wet age-related macular degeneration (wAMD). Eylea® is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and placental growth factor

  • 31 May 2013